WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Vermont to grant professional licenses, regardless of immigration status, to ease labor shortageHow just one horrible moment in your past could cause ALZHEIMER'S, according to new studyTerrifying moment knifeConor McGregor's dad Tony, 64, is hospitalized in Ireland after major health scareFrench police killed a suspect planning to set fire to a synagogueFIFA to seek legal advice on a Palestinian proposal to suspend Israel from international soccerMichael Cohen is torn to shreds by Trump's attorneys in blistering crossJuan Soto says he's open to inGeorgia Republican files for divorce from glamorous oncologist after seven childrenIt's not a rock, it's the Athens Rock Lobsters. New minor league team honors B
2.3775s , 6498.2265625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Scope news portal